Directorate Changes

Abingdon Health

24/03/2025 07:00

RNS Number : 7535B

Abingdon Health PLC

24 March 2025

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Directorate Changes

Changes to CEO role and appointment of Non-Executive Director

 

York, U.K.  24 March 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces changes to the Board of Directors.

 

Chris Yates, having performed the role of CEO of Abingdon Health for 10 years, has been appointed to the new role of President, Abingdon Health USA Inc. ("Abingdon Health USA"), with overall responsibility for the US business and for commercial activities globally, including recently acquired subsidiaries CS (Life Sciences) Group and IVDeology. Chris will be a Director of Abingdon Heath USA and stands down as CEO and Director of Abingdon Health plc effective today. The role of Group CEO has been incorporated into Chris Hand's role as Executive Chairman.

 

Dr Katie Brenner will be appointed on 1 April 2025 as an additional Independent Non-Executive Director at Abingdon Health plc. Dr Brenner is based in Madison, WI, USA and founded bluDiagnostics, a company specialising in lateral flow testing with an associated app to allow at-home monitoring of female fertility using saliva samples. She sold bluDiagnostics to Amazon in 2020 and remained there until 2024. Dr Brenner has a PhD in Bioengineering from Caltech and has a BS and MS from Stanford University in Electrical Engineering.

 

                                    

Dr Katie Brenner

 

Once the changes have been made the Abingdon Health plc Board will comprise two Executive Directors and two Non-Executive Directors:

 

Executive Directors

·    Dr Chris Hand, Executive Chairman

·    Tom Hayes, Chief Financial Officer

 

Non-Executive Directors

·    Mary Tavener, Senior Independent Non-Executive Director

·    Dr Katie Brenner, Independent Non-Executive Director

 

Max Duckworth, an early investor and previous Board member (pre-IPO), sits as a Board Observer.

 

Chris Yates, President of Abingdon Health USA Inc., commented: "It's been an honour and a privilege to lead Abingdon Health.  After nearly ten years of service as CEO I've made the decision to transition to a new commercially focused role, where I believe I can best contribute to our future growth. I would like to thank the Board for their flexibility and support in facilitating this change. I am looking forward to focusing my efforts on building the Abingdon Health USA operations and the Group's global commercial activities. I would also like to take this opportunity to welcome Katie to the Board."

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "As the Abingdon Health Group continues to grow, with an increasing focus on US lateral flow and compliance markets, I am pleased that Chris Yates has accepted the challenge of managing our US operations and global commercial activities. The role of Group CEO will lapse and be incorporated into my recently announced role of Executive Chairman. The addition of Dr Katie Brenner as a Non-Executive Director significantly strengthens our Board and will provide us with invaluable experience as we continue to grow the business, and I'd like to welcome Katie to the Board at this exciting time for Abingdon Health. Tom Hayes and Mary Tavener add further to those skills, and I would like to thank them for their continued support.

 

"As a co-founder of Abingdon Health with Chris Yates, I'd like to offer my thanks to him for the tremendous job he has done as CEO over the past 10 years, to thank him for his flexibility and commitment in moving to the important role of President, Abingdon Health USA Inc., and to wish him success in that role as we move forward."

 

Additional Disclosures Required under the AIM Rules for Companies

 

Dr Sarah Katherine Brenner (aged 45) has held the following directorship or partnerships in the past five years:

 

Current directorships/partnerships
Amulet, Inc
Previous directorships/partnerships (last five years)
bluDiagnostics, Inc

 

Dr Brenner and persons closely associated (as defined under MAR) with Dr Brenner do not hold any shares in the Company.

 

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

 

Enquiries:

 

Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand, ExecutiveChairman
Via Walbrook PR
Tom Hayes, CFO
Zeus (Sole Broker and Nominated Adviser)
Tel: +44 (0)20 3829 5000
Antonio Bossi / Alexandra Campbell-Harris (Corporate Finance)
Fraser Marshall (Corporate Broking)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
Phillip Marriage
+44 (0)7867 984 082


 

 

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its services to an international customer base.

 

The Group's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internally (e.g. Quality Management Systems) and externally (e.g. critical suppliers), management reviews and presentations, training and mentoring.

 

Abingdon Simply TestTM range of self-tests are marketed via an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply TestTM e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range and other selected self-test products, such as the saliva pregnancy test, SalistickTM, is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England with CDMO facilities in both York, UK and Madison, Wisconsin, USA. For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOAPPUBWWUPAGMG